Effect of aluminum accumulation on bone and cardiovascular risk in the current era

Imagem de Miniatura
Arquivos
art_CARBONARA_Effect_of_aluminum_accumulation_on_bone_and_cardiovascular_2023.PDF (490.69 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
CARBONARA, Cinthia E. M.
ROZA, Noemi A. V.
QUADROS, Kelcia R. S.
FRANCA, Renata A.
ESTEVES, Andre B. A.
PAVAN, Celia R.
BARRETO, Joaquim
SPOSITO, Andrei C.
Citação
PLOS ONE, v.18, n.4, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundThe prevalence of aluminum (Al) intoxication has declined over the past 3 decades. However, different groups still report on the diagnosis of Al in bone. Prolonged and low-intensity exposures to Al may not be captured by serum Al measurements, preventing its proper diagnosis. We hypothesize that bone Al accumulation may be related to bone and cardiovascular events in the current Era. AimsTo detect the diagnosis of bone Al accumulation; to explore bone and cardiovascular consequences of Al accumulation. MethodsThis is a sub-analysis of The Brazilian Registry of Bone Biopsy, a prospective, multicentre cohort, with a mean follow-up of 3.4 years, including patients with CKD undergoing bone biopsy; bone fracture and major cardiovascular events (MACE) were adjudicated; Al accumulation was identified by solochrome-azurine staining; history of previous Al accumulation was registered based on information provided by the nephrologist who performed the bone biopsy; bone histomorphometry parameters, clinical data, and general biochemistry were registered. Results275 individuals were considered; 96 (35%) patients have diagnosed with bone Al accumulation and were younger [50 (41-56) vs. 55 (43-61) years; p = 0.026], had lower body mass index [23.5 (21.6-25.5) vs. 24.3 (22.1-27.8) kg/m(2); p = 0.017], higher dialysis vintage [108 (48-183) vs. 71 (28-132) months; p = 0.002], presented pruritus [23 (24%) vs. 20 (11%); p = 0.005], tendon rupture [7 (7%) vs. 3 (2%); p = 0.03) and bone pain [2 (0-3) vs. 0 (0-3) units; p = 0.02]. Logistic regression reveals that prior bone Al accumulation [OR: 4.517 (CI: 1.176-17.353); p = 0.03] and dialysis vintage [OR: 1.003 (CI: 1.000-1.007); p = 0.046] as independent determinants of bone Al accumulation; minor perturbations in dynamic bone parameters and no differences in bone fractures rate were noted; MACE was more prevalent in patients with bone Al accumulation [21 (34%) vs. 23 (18%) events; p = 0.016]. Cox regression shows the actual/prior diagnosis of bone Al accumulation and diabetes mellitus as independent predictors for MACE: [HR = 3.129 (CI: 1.439-6.804; p = 0.004) and HR = 2.785 (CI: 1.120-6.928; p = 0.028]. ConclusionsAn elevated proportion of patients have bone Al accumulation, associated with a greater prevalence of bone pain, tendon rupture, and pruritus; bone Al accumulation was associated with minor perturbations in renal osteodystrophy; actual/prior diagnosis of bone Al accumulation and diabetes mellitus were independent predictors for MACE.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/56344
Referências
  1. Araújo SMHA, 2003, KIDNEY INT, V63, pS54, DOI 10.1046/j.1523-1755.63.s85.13.x
  2. Bohrer D, 2007, NEPHROL DIAL TRANSPL, V22, P605, DOI 10.1093/ndt/gfl569
  3. Bover J, 2014, SEMIN NEPHROL, V34, P626, DOI 10.1016/j.semnephrol.2014.09.008
  4. CHAZAN JA, 1991, ARCH INTERN MED, V151, P319, DOI 10.1001/archinte.151.2.319
  5. Couser WG, 2011, KIDNEY INT, V80, P1258, DOI 10.1038/ki.2011.368
  6. Oliveira Rodrigo Bueno de, 2014, Braz. J. Nephrol., V36, P352, DOI 10.5935/0101-2800.20140050
  7. Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
  8. Dos Reis LM, 2007, J BONE MINER METAB, V25, P400, DOI 10.1007/s00774-007-0778-4
  9. Douthat WG, 2003, NEFROLOGIA, V23, P47
  10. Drüeke TB, 2002, NEPHROL DIAL TRANSPL, V17, P13, DOI 10.1093/ndt/17.suppl_2.13
  11. Dunea G, 2001, ASAIO J, V47, P192, DOI 10.1097/00002480-200105000-00002
  12. El-Hussainy EMA, 2016, CAN J PHYSIOL PHARM, V94, P868, DOI 10.1139/cjpp-2015-0446
  13. Fernandez-Martin JL, 1998, NEPHROL DIAL TRANSPL, V13, P78, DOI 10.1093/ndt/13.suppl_3.78
  14. Garcia-Garcia G, 2015, KIDNEY INT, V87, P251, DOI [10.1038/ki.2014.369, 10.5935/0101-2800.20150003]
  15. Goldenstein PT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068870
  16. González-Revaldería J, 2000, CLIN CHEM LAB MED, V38, P221, DOI 10.1515/CCLM.2000.032
  17. Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
  18. Hernandez JD, 2008, CLIN J AM SOC NEPHRO, V3, pS164, DOI 10.2215/CJN.00460107
  19. Hsu CW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35217-6
  20. Hsu CW, 2016, THER CLIN RISK MANAG, V12, P1417, DOI 10.2147/TCRM.S113829
  21. Jaffe JA, 2005, AM J KIDNEY DIS, V46, P316, DOI 10.1053/j.ajkd.2005.04.020
  22. Jean G, 2011, NEPHRON CLIN PRACT, V118, pC211, DOI 10.1159/000321642
  23. Jha V, 2012, NEPHROL DIAL TRANSPL, V27, P32, DOI 10.1093/ndt/gfs113
  24. Kidney Disease: Improving Global Outcomes, 2013, KIDNEY INT SUPPL, V3, P1, DOI 10.1038/KISUP.2012.76
  25. Lavergne V, 2012, PERITON DIALYSIS INT, V32, P645, DOI 10.3747/pdi.2011.00203
  26. Li PKT, 2021, BLOOD PURIFICAT, V50, P1, DOI 10.1159/000506966
  27. Liu Z, 2018, REPROD TOXICOL, V81, P93, DOI 10.1016/j.reprotox.2018.07.081
  28. Malluche HH, 2002, NEPHROL DIAL TRANSPL, V17, P21, DOI 10.1093/ndt/17.suppl_2.21
  29. Meira Rodrigo Dias de, 2018, Braz. J. Nephrol., V40, P201, DOI [10.1590/2175-8239-jbn-3882, 10.1590/2175-8239-JBN-3882]
  30. Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
  31. Carbonara CEM, 2020, J BRAS NEFROL, V42, P138, DOI [10.1590/2175-8239-jbn-2019-0045, 10.1590/2175-8239-JBN-2019-0045]
  32. Morena Marion, 2005, Hemodial Int, V9, P37, DOI 10.1111/j.1492-7535.2005.01116.x
  33. National Kidney Foundation, 2003, AM J KIDNEY DIS, V42, pS1
  34. Naylor KL, 2014, KIDNEY INT, V86, P810, DOI 10.1038/ki.2013.547
  35. Prasad N, 2015, KIDNEY DIS-BASEL, V1, P165, DOI 10.1159/000441816
  36. Saleem A, 2020, DRUG CHEM TOXICOL, V43, P298, DOI 10.1080/01480545.2018.1525394
  37. Sandhu G, 2011, AM J KIDNEY DIS, V57, P523, DOI 10.1053/j.ajkd.2010.10.051
  38. Schmidt PM, 2016, TOXICOL APPL PHARM, V313, P109, DOI 10.1016/j.taap.2016.10.023
  39. See EJ, 2022, NEPHROL DIAL TRANSPL, V37, P159, DOI 10.1093/ndt/gfaa343
  40. Seidowsky A, 2018, NEPHROL THER, V14, P35, DOI 10.1016/j.nephro.2017.04.002
  41. SMITH GD, 1987, KIDNEY INT, V32, P96, DOI 10.1038/ki.1987.177
  42. Sola L, 2020, KIDNEY INT SUPPL, V10, pE55, DOI 10.1016/j.kisu.2019.11.009
  43. Tsai MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34799-5
  44. van Landeghem GF, 1998, CLIN NEPHROL, V50, P69
  45. VanLandeghem GF, 1997, EXP NEPHROL, V5, P239
  46. VEDI S, 1984, METAB BONE DIS RELAT, V5, P69, DOI 10.1016/0221-8747(83)90004-8
  47. Wang TL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190008
  48. Zhou LF, 2022, BIOL TRACE ELEM RES, V200, P308, DOI 10.1007/s12011-021-02646-w

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - ODS/03